Browse the evidence

Tirzepatide achieved MASH resolution with no worsening of fibrosis in a significantly higher percentage of patients than placebo.

Tirzepatide may be a promising treatment option for patients with MASH, potentially improving liver health.

More patients in the tirzepatide group achieved a 1-stage or greater fibrosis improvement without worsening of MASH compared to placebo.

Tirzepatide may help improve liver fibrosis in patients with MASH.

Tirzepatide has been approved for the treatment of adults with type 2 diabetes who are overweight/obese or have weight-related comorbidities.

Tirzepatide is a viable treatment option for managing type 2 diabetes in specific patient populations.

Lacto-ovo-vegetarians (LOV) and non-vegetarians (NV) showed similar increases in quadriceps femoris muscle thickness (QFMT) after 12 weeks of strength training (ST) (LOV: 9.2 ± 5.4 mm; NV: 5.5 ± 8.1 mm).

Both vegetarians and non-vegetarians can achieve similar muscle growth from strength training.

Both groups experienced similar improvements in knee extension one-repetition maximum (1RM) after 12 weeks of ST (LOV: 24.7 ± 11.1 kg; NV: 21.6 ± 9.8 kg).

Strength training can enhance strength performance similarly in both vegetarians and non-vegetarians.

Lacto-ovo-vegetarians had lower protein consumption than non-vegetarians throughout the study but still achieved adequate protein intake.

Adequate protein intake can be achieved even with lower consumption in vegetarians.

Innovative solutions are needed to implement sustainable lifestyle modification interventions for T2D.

Practitioners should advocate for and develop innovative strategies to enhance lifestyle intervention adherence.

The importance of specific protein sources appears to differ by sex.

Further research is needed to understand how different protein sources affect lean mass in men and women.

There is a distinct correlation between type 2 diabetes status and the likelihood of heart failure.

Recognizing this correlation can guide healthcare providers in monitoring and managing heart health in diabetic patients.

GLP-1 receptor agonists have demonstrated cardioprotection in patients with type 2 diabetes and heart failure.

Incorporating GLP-1RAs into treatment plans may improve cardiovascular outcomes in diabetic patients.

Efficient lipid-lowering drugs have substantially reduced the incidence and mortality for cardiovascular disease (CVD).

Practitioners should consider lipid-lowering drugs as effective interventions for reducing CVD risk.

Ribosomal biogenesis regulates the dose-response relationship between training volume and muscle hypertrophy.

Understanding the role of ribosomal biogenesis can help optimize resistance training protocols for hypertrophy.

Weight gain within the first 6 months was associated with increased risk of HbA1c >7.5% and subsequent cardiovascular disease (CVD) with a hazard ratio (HR) of 1.03.

Clinicians should monitor weight changes in T2D patients as it may impact glycemic control and cardiovascular health.

Weight gain at 1 year was associated with increased risk of HbA1c >7.5% (HR 1.05) and kidney disease (HR 1.03).

Weight management is crucial for T2D patients to prevent worsening glycemic control and kidney disease.

Weight gain was associated with lower diabetes treatment satisfaction.

Healthcare providers should address weight management to improve patient satisfaction with diabetes treatment.

Obesity increases the risk of postoperative complications following elective surgery.

Surgeons should consider obesity as a significant risk factor when planning surgeries.

An interdisciplinary approach is necessary for effective weight loss treatment in obese patients before joint replacement surgery.

Healthcare teams should collaborate across disciplines to optimize weight loss strategies for these patients.

Soy isoflavones may be helpful in treating conditions such as insulin resistance, inflammation, cardiovascular disease, and intestinal dysbiosis.

Soy isoflavones could be considered as a potential treatment option for various metabolic conditions associated with PCOS.

Diabetic patients had a significantly higher percentage excess weight loss (%EWL) than nondiabetics at 12 and 24 months post LSG.

Diabetic patients undergoing LSG may experience greater weight loss compared to nondiabetic patients, which can inform clinical expectations.

Diabetic patients with BMI >40 kg/m² had significantly higher %EWL than patients with BMI ≤40 at 12 and 24 months.

Patients with higher BMI may achieve better weight loss results post-surgery, which can guide treatment decisions.

The differences in MPS rates between whey and soy protein may be due to higher leucine content and more rapid leucinemia with whey.

Understanding the role of leucine may help in selecting protein sources for muscle health in the elderly.

Patients showed improvements in mental health scores, with SF-12 mental scores changing by 2.8 points at 6 months and 2.3 points at 18 months.

Improving mental health is a crucial component of lifestyle interventions for obesity.

CRDs improved hepatic stress (GGT: SMD = -6.08 U/L) and renal function (UACR: SMD = -0.19).

CRDs may be beneficial for improving liver and kidney health in adults.

Emerging pharmacologic agents like tirzepatide and bimagrumab show promise in changing standards of care for cardiometabolic disease management.

Healthcare providers should stay informed about these emerging treatments as they may significantly impact patient care.